This, in turn, allows the interaction between SET and MYND Domain Containing 4 (SMYD4) and the unmethylated Nanog promoter, leading to the activation of Nanog expression in Nanog-negative tumor cells, thereby driving the transition of CSCs [59]. The gene discussed is NANOG; the disease is neoplasm.